Sibutramine: current status as an anti-obesity drug and its future perspectives

By Sharma Bikash   Henderson David C  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 12, 2008-08 ,pp. : 2161-2173

Informa Healthcare

Access to resources Recommend Favorite

The discovery and status of sibutramine as an anti-obesity drug

By Luque C.A.   Rey J.A.  

European Journal of Pharmacology, Vol. 440, Iss. 2, 2002-04 ,pp. : 119-128

Elsevier

Access to resources Recommend Favorite

Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status

By Parker E.   Van Heek M.   Stamford A.  

European Journal of Pharmacology, Vol. 440, Iss. 2, 2002-04 ,pp. : 173-187

Elsevier

Access to resources Recommend Favorite

Anti-obesity drug development

By Bays Harold   Dujovne Carlos  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 9, 2002-09 ,pp. : 1189-1204

Informa Healthcare

Access to resources Recommend Favorite

Neuropeptide Y1 and Y5 Receptor Antagonists as Potential Anti-Obesity Drugs: Current Status

By  

Mini Reviews in Medicinal Chemistry, Vol. 14, Iss. 11, 2014-10 ,pp. : 896-919

Bentham Science Publishers

Access to resources Recommend Favorite